SRPT (Sarepta Therapeutics) Marketable Securities : $252 Mil (As of Dec. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sarepta Therapeutics's Marketable Securities for the quarter that ended in Dec. 2024 was $252 Mil.

Sarepta Therapeutics's annual Marketable Securities increased from Dec. 2022 ($1,023 Mil) to Dec. 2023 ($1,248 Mil) but then declined from Dec. 2023 ($1,248 Mil) to Dec. 2024 ($252 Mil).

Sarepta Therapeutics Marketable Securities Historical Data

The historical data trend for Sarepta Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Marketable Securities Chart

Sarepta Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

435.92

1,022.60

1,247.82

251.78

Sarepta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Marketable Securities	Get a 7-Day Free Trial															1,247.82	963.45	1,076.85	1,000.53	251.78

Sarepta Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Sarepta Therapeutics (NAS:SRPT) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sarepta Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

SRPT:Mexico 0L35:UK AB3A:Germany AB3A:Germany S1RP34:Brazil

Address

215 First Street, Suite 415, Cambridge, MA, USA, 02142

Website

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Executives

Claude Nicaise	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf	director	OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Kathryn Jean Boor	director	3736 S. MAIN STREET, MARION NY 14505
Ian Michael Estepan	officer: Chief Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Michael Andrew Chambers	director	215 FIRST STREET, CAMBRIDGE MA 02142
Bilal Arif	officer: Chief Tech Ops Officer	215 FIRST STREET, CAMBRIDGE MA 02129
Ryan Edward Brown	officer: SVP, General Counsel	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram	director, officer: President & CEO	2525 DUPONT DR, IRVINE CA 92612
Louise Rodino-klapac	officer: Chief Scientific Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens	director	6701 KAISER DRIVE, FREMONT CA 94555
Joseph Bratica	officer: Principal Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton	officer: SVP, General Counsel	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin	director	333 LAKESIDE DRIVE, FOSTER CITY X1 94404